Behavioral responses of long-term hyperprolactinaemic rats

Gastric ulceration and expression of prolactin receptor in the brain in Hatano high- and low-avoidance rats

Recently, prolactin was shown to inhibit the development of stress-induced ulcers. However, the mechanism for suppression of gastric ulcers by prolactin has not been clarified. Hatano high-avoidance (HAA) and low-avoidance (LAA) strains of rats were originally selected and bred from Sprague-Dawley rats based on shuttle-box tasks. The present study focused on the relationships among gastric ulceration and endocrine response with special reference to prolactin secretion and restraint stress in water of HAA and LAA rats. The restraint stress induced an elevation of plasma concentrations of ACTH, corticosterone, and prolactin. Peak levels of plasma ACTH during stressful condition were significantly higher in HAA rats than in LAA rats, while peak levels of prolactin were significantly lower in HAA rats than in LAA rats. The gastric erosion index was significantly higher in HAA rats than in LAA rats 7 h after restraint stress in water. The numbers of prolactin- receptor-positive cells determined by immunohistochemistry in the paraventricular nucleus was significantly increased in LAA rats than in HAA rats 7 h after restraint stress in water. These results indicate that HAA rats were more sensitive than LAA rats to restraint stress in water. The strain differences in gastric ulceration under stress may be involved in peripheral prolactin secretion and central prolactin receptor expression. The expression of prolactin receptor in the paraventricular nucleus may be important in suppressing gastric ulceration.

Effect of lactation on the expression of audiogenic seizures: association with plasma prolactin profiles

Female Wistar rats and Wistar audiogenic rats (WARs) were used to investigate the potential roles of prolactin (PRL) and progesterone in the modulation of seizure expression. Animals were screened for seizure severity in both groups. All WARs at least displayed tonic-clonic convulsions followed by clonic spasms (TC) whereas none of the Wistar rats displayed seizures (Resistant). After seizures the plasma level of PRL in nulliparous female WARs increased about 8-fold compared to their basal levels and to the levels of Resistant animals. This value was still significantly higher than basal levels 15 min later. Lactation produced a decrease in the TC proportion in seizures in WARs both with and without pups. Two sub-populations of animals could be characterized: one that had TC suppressed (low seizure severity; LSS) and one that did not (high seizure severity; HSS). In animals of the LSS subgroup, either with or without pups, seizure severity decreased gradually and lowest values were seen on the 30th day after delivery. The temporal profile of plasma PRL during a 90-min period of suckling without sound stimulation showed significantly higher levels for LSS, the HSS levels being similar to those of the Resistant group. A progressive decrease in the group means for progesterone plasma concentration between the 9th and 29th days of lactation was detected in Resistant rats (P<0.05) but not in WARs. No significant differences between groups were revealed by comparison of the overall means. Taken together these data confirm the presence of a clear-cut post-ictal PRL peak after TC with a decrease in seizure severity in female WARs with and without pups. An eventual long-term role of PRL in modulating seizure activity might be related to the multifactorial physiological conditions of both pregnancy and lactation.

The "low-dose" concept and the paradoxical effects of prolactin on grooming and sexual behavior

The effects of prolactin on animal behavior include the stimulation of novelty-induced grooming in rats. This effect has been demonstrated in hyperprolactinaemic animals bearing pituitary homografts under the kidney capsule or after intracerebroventricular (i.c.v.) administration of prolactin. Since plasma prolactin levels in hyperprolactinaemic rats are similar to those of animals injected with low doses of rat prolactin, we studied the effects of this hormone injected subcutaneously (s.c.) in a dose range of 5-50 microg/kg. Novelty-induced grooming was enhanced only in rats injected with 5 or 10 microg/kg rat prolactin, whereas no effect was observed after the s.c. injection of the higher dose. The sexual behavior of male rats is also affected by prolactin. Male rats with normal mating activity showed enhanced sexual behavior when injected s.c. with rat prolactin (5, 10 or 50 microg/kg). In animals with poor sexual performance or in impotent rats, prolactin (5 or 10 microg/kg, but not 50 microg/kg) restored the full pattern of sexual behavior. An increased lordosis quotient was also observed in ovariectomized rats treated with prolactin 5 or 10 microg/kg. These results suggest that, besides the duration of hyperprolactinaemia, the effective level of plasma prolactin is important for the expression of the behavioral effects of this hormone.

Dual modulation of male sexual behavior in rats by central prolactin: relationship with in vivo striatal dopaminergic activity

Prolactin (PRL) appears to be localized in several brain structures. Central, behaviorally meaningful, neural actions of this protein have been demonstrated in a large number of studies. The present report describes sexual behavioral and in vivo neurochemical data obtained from adult male rats injected intracerebroventricularly acutely (10 micrograms) or chronically (5 days; 10 micrograms/day) with ovine prolactin (oPRL). The extracellular striatal concentrations of dopamine and serotonin metabolites were estimated by HPLC measurements in microdialysis perfusates. A single (10 micrograms) administration of oPRL facilitated sexual activity and increased extracellular striatal DOPAC, HVA and 5HIAA levels, whereas five daily intracerebroventricular injections of oPRL, decreased the sexual behavior and reduced DOPAC and HVA striatal extracellular concentrations in response to a central oPRL injection. These results show that acute and chronic central oPRL treatments have stimulatory and inhibitory effects on male sexual behavior, respectively. In addition, the results suggest that striatal dopaminergic activity is increased and decreased by acute and 5-day central oPRL treatments. These data suggest that behavioral effects of PRL occur simultaneously with changes in striatal dopaminergic activity.

Effects of acute and long-term domperidone treatment on prolactin and gonadal hormone levels and sexual behavior of male and female rats

Domperidone (DOMP), a dopamine D2 blocker that is unable to cross the blood-brain barrier, is an experimental tool used to induce hyperprolactinemia. Acute and long-term DOMP administration was tested in male and female rats for its effects on sexual behavior and plasma gonadal hormone levels. DOMP (4.0 mg/kg) was injected I.P. either acutely or daily for 30 days. Acute treatment failed to modify any behavioral parameter observed. The 5-day treatment stimulated and the 30-day treatment failed to inhibit sexual behavior of male rats. Serum testosterone levels were significantly reduced after 30 days of treatment in male rats. The 30-day treatment also inhibited sexual behavior and enhanced plasma progesterone levels in ovariectomized and intact female rats, respectively. The present results may be due to DOMP-induced long-term hyperprolactinemia. Alternatively, blockade of dopamine peripheral receptors induced by this treatment may also be responsible for the behavioral changes reported here. Moreover, these data suggest that female rats are more susceptible than males to the behavioral effects of long-term hyperprolactinemia.

Domperidone induces a probenecid-sensitive rise in immunoreactive prolactin in cerebroventricular perfusates in female rats

The present study examined immunoreactive prolactin (ir-PRL) access into the cerebrospinal fluid (CSF) by monitoring ir-PRL levels in the blood and cerebroventricular perfusates of ovariectomized (ovx) rats treated with the dopamine antagonist, domperidone (DOMP). In Expt. 1 PRL plasma levels were measured in rats treated with DOMP i.p. (2.5, 5.0 and 10.0 mg/kg). All doses of DOMP significantly increased PRL plasma levels. In Expt. 2 animals were treated i.p. with DOMP (10 mg/kg) or DOMP plus the active transport blocking agent, probenecid (PROB; 250 mg/kg). Plasma PRL and ir-PRL in cerebroventricular perfusates were measured in separate sets of animals using catheters and a push-pull perfusion system, respectively. DOMP induced an increase in plasma PRL that was followed 30-40 min later by a rise in ventricular perfusates ir-PRL levels. PROB treatment induced a greater increase in plasma PRL levels in DOMP-treated animals, but delayed the DOMP-induced increase in ir-PRL ventricular perfusate ir-PRL levels. The delay in the rise of ir-PRL in ventricular perfusates observed in rats treated with DOMP plus PROB may be due to a PROB's interference with the transport of PRL from the blood into CSF. These results suggest that under some conditions ir-PRL in CSF originates from the pituitary.

A comparison of bromopride and domperidone effects on rat conditioned avoidance and motor activity

Acute intraperitoneal administration of bromopride (BRO) and domperidone (DOMP), two dopamine D2 blockers used as antiemetics in gastroenterology, were tested in male rats for effects on motor activity and on active and inhibitory conditioned behaviour. BRO dose-dependently depressed ambulation and rearing, impairing the performance of active conditioned avoidance (CAR) even when injected prior to the retention session. It also impaired inhibitory avoidance responses (IAR). All these effects were dose-dependent. DOMP was ineffective at modifying any of the above described parameters. These results suggest that BRO exerts neuroleptic effects which are neither mediated by actions on peripheral dopamine receptors nor by increased prolactin levels. These data also suggest that DOMP is a more appropriate drug for gastroenterology.

Prolactin as a protective factor in stress-induced biological changes

The adenohypophyseal hormone prolactin (PRL) is released during stress of physical and psychological nature. In animals, this hormone facilitates adaptive behavior, induces analgesia, and enhances grooming behavior. It also reduces corticosterone secretion and the incidence of gastric ulcers induced by physical stress. It is possible that PRL plays a protective role against stress-induced biological modifications in animals.

Tamoxifen counteracts estradiol induced effects on striatal and hypophyseal dopamine receptors

We investigated the ability of Tamoxifen (TAM), an antiestrogen drug, to counteract the modifications induced by estrogens on dopamine (DA) receptors on striatum and on adenohypophysis of ovex female rats. Subacute treatment with 17 beta-estradiol (E2) at both low (0.1 micrograms/kg) and high (20 micrograms/kg) doses confirmed its ability to increase the number of striatal 3H-Spiperone (3H-SPI) binding sites in a dose dependent manner. By contrast in the pituitary, only high doses of estrogen were effective in reducing the number of DA receptors. We treated ovex female rats for 15 days with TAM alone or associated with E2, to see if these estrogenic effects could be suppressed by an antiestrogenic drug. TAM did not affect the number of striatal DA receptors, but significantly increased the adenohypophyseal DA binding sites, without varying their affinity. No changes were observed in pituitary and striatal DA receptor density, even when TAM was injected in association with estradiol.

IN CONCLUSION

TAM is able to counteract the effects estrogens have on DA receptors. However there is some evidence that it could influence the pituitary DA systems independently of its antiestrogenic activity.

Influence of hypophysectomy on dopamine receptors and dopaminergic behaviors

Hypophysectomy (Hypox) has been proposed to alter the behavioral and biochemical indices of striatal dopamine (DA) function. Since the regulation of striatal DA receptors by hormones may involve the pituitary, it was relevant to reevaluate the effects of Hypox in male and female rats. Behaviorally, dopaminergic agonists exerted enhanced activity in Hypox male and female rats. It has been suggested that these changes are due to altered metabolism since no increase in the DA receptor populations was observed. Dopaminergic antagonists showed equivalent behavioral actions in male and female rats, whether intact or Hypox. Biochemically, neither the density nor the affinity of the striatal DA receptors is altered by Hypox in female rats for 1-2 weeks or male rats for 5-6 weeks. However, in female rats at 5-6 weeks after Hypox there is a significant decrease in receptor number. This decrease in density is not reflected in behavioral changes to either DA receptor agonists or antagonists. Therefore, all dopaminergic behavioral changes do not result from alterations in DA receptors and changes in DA receptors do not necessarily dictate altered behavioral responses to dopaminergic agents.

The possible role of 2-hydroxyestradiol in the development of estrogen-induced striatal dopamine receptor hypersensitivity

In the present study, we have confirmed the existence of a biphasic response in striatal dopamine receptor sensitivity following the administration of estradiol benzoate (EB). This biphasic response consists of a hyposensitive phase 24 h after the last injection of EB, followed by a hypersensitive phase 72 h after the last injection of EB. In contrast to this, the administration of 2-hydroxyestradiol (2-OHE2), a catechol metabolite of estrogen, resulted in a striatal dopamine receptor hypersensitivity at both 24 and 72 h after the last injection of 2-OHE2. Studies on the in vivo metabolism of [3H]estradiol to its [3H]catechol metabolites indicated that the administration of piperonyl butoxide (PBO; a microsomal enzyme inhibitor) significantly decreased the level of [3H]catechol metabolites of [3H]estradiol in the striatum and in the medial basal hypothalamus. In addition, PBO administration resulted in about a 7-fold decrease in the ability of estradiol to induce a striatal dopamine receptor hypersensitivity. These data indicate that the biphasic response in striatal dopamine receptor sensitivity following estrogen, may be mediated by separate molecular mechanisms. The association of the hypersensitive phase with pharmacological doses and/or treatment paradigms, the development of a similar hypersensitivity following the administration of the 2-OHE2 metabolite of estrogen and the attenuation of the estrogen-induced striatal dopamine receptor hypersensitivity in PBO pretreated animals all suggest that this striatal dopamine receptor hypersensitivity may be mediated, at least in part, by the catecholestrogens.

Enhancement of hypophysectomy-induced dopamine receptor hypersensitivity in male rats by chronic haloperidol administration

It has been reported that hypophysectomy (HYPOX) would antagonize the development of a neuroleptic-induced dopamine receptor hypersensitivity, and suggested that the neuroleptic-induced dopamine receptor hypersensitivity may be mediated by the neuroleptic-induced hyperprolactinemia. Conversely, we and others have reported on the ability of HYPOX animals to develop a neuroleptic-induced dopamine receptor hypersensitivity. The present study was undertaken to define the possible role(s) of prolactin in the modulation of striatal dopamine receptor sensitivity. The data from these studies indicate: that HYPOX alone will result in the development of a striatal dopamine receptor hypersensitivity; that the HYPOX-induced dopamine receptor hypersensitivity could be increased by the chronic administration and withdrawal of haloperidol; that administration of prolactin to HYPOX rats would partially antagonize the development of the neuroleptic-induced dopamine receptor hypersensitivity; and that the administration of prolactin alone had minimal effects on the apomorphine-induced behavior or neurochemistry of the HYPOX animals. These results suggest that the neuroleptics do not require the presence of a pituitary secretion (specifically, prolactin) to induce a striatal dopamine receptor hypersensitivity; however, they do indicate that a pituitary secretion, perhaps prolactin, may have the ability to modulate striatal dopamine sensitivity.

Prolactin-enhanced grooming behavior: interaction with ACTH

The interaction between prolactin (PRL) and ACTH in enhancing grooming behavior after intracerebroventricular (i.c.v.) administration was investigated in intact and endogenously hyperprolactinaemic rats. In intact rats, 4 h after the i.c.v. injection of rat PRL or ACTH, a subsequent administration of ACTH or rat PRL did induce similar excessive grooming as observed after the first injections. In hyperprolactinaemic rats, which displayed excessive grooming 12 days after homografting adenopituitaries under the kidney capsule, i.c.v. injection of rat PRL failed to enhance further the grooming activity while this behavior was substantially enhanced by i.c.v. injection of ACTH1-24. Twenty-six days after surgery, when the grooming activity of hyperprolactinaemic rats was at the same level as control animals, the i.c.v. injection of rat PRL was effective in inducing excessive grooming in control but not in hyperprolactinaemic animals. In contrast, at this time the i.c.v. injection of ACTH1-24 induced again excessive grooming in both hyperprolactinaemic and control rats. Accordingly, there was no cross-tolerance between PRL and ACTH in inducing excessive grooming, but hyperprolactinaemic rats became hyposensitive to exogenous PRL. It is suggested that although PRL and ACTH may affect common neurotransmitter systems in the brain, the two hormones probably act on independent neural mechanisms in inducing excessive grooming in the rat.